Cytori Therapeutics to Present at the AGEdwards Emerging Growth Conference
Posted on: Wednesday, 13 September 2006, 09:01 CDT
Cytori Therapeutics, Inc., (NASDAQ:CYTX) (Frankfurt:XMPA) will present and provide an audio webcast of its corporate presentation at AGEdwards' Emerging Growth Conference 2006 in New York, N.Y., on Wednesday, September 20th at 9:30 a.m. Eastern Daylight Time.
The audio webcast may be accessed under "Events & Webcasts" in the Investor Relations section of the Company's website at http://www.cytoritx.com. The webcast will be available live and by replay one hour after the presentation on the company's website and archived for 14 days.
About Cytori Therapeutics
Cytori Therapeutics, Inc., (NASDAQ:CYTX) (Frankfurt:XMPA) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Source: Business Wire
Related Articles
- Cytori Therapeutics to Webcast 2nd Quarter Results on August 8, 2008
- Cytori Selected By Fraunhofer Society to Develop New Stem and Regenerative Cell-Based Treatments for Stroke
- Cytori Therapeutics to Webcast 2nd Quarter Results on August 14, 2007
- Cytori Therapeutics to Webcast 2007 1st Quarter Results on May 11, 2007
- Cytori Therapeutics to Webcast 2006 4th Quarter and Year End Results on March 30, 2007
- Cytori Therapeutics to Webcast Second Quarter Financial Results on August 14, 2006
- First Three Patients Treated in Adipose Stem and Regenerative Cell Clinical Safety and Feasibility Study for Breast Reconstruction; Represents First Clinical Use of Cytori's Regenerative Cell Processing System
- Cytori Therapeutics Reports Benefit of Adipose Stem and Regenerative Cells in Reconstructive Surgery From Preclinical Study
- Cytori Therapeutics Demonstrates Adipose Stem and Regenerative Cells Reduce Incidence of Arrhythmia After Heart Attacks in Preclinical Study
- Clinical Safety and Feasibility Study Initiated Using Adipose Stem and Regenerative Cells in Breast Reconstruction Procedures
 |
 |
User Comments (0)
RSS Feeds